List of Excipients in Branded Drug ADAPALENE AND BENZOYL PEROXIDE GEL, 0.1%/2.5%

Generic Drugs Containing ADAPALENE AND BENZOYL PEROXIDE GEL, 0.1%/2.5%

Company	Ingredient	NDC	Excipient
Encube Ethicals Inc	adapalene and benzoyl peroxide gel, 0.1%/2.5%	21922-052	CARBOMER HOMOPOLYMER TYPE C
Encube Ethicals Inc	adapalene and benzoyl peroxide gel, 0.1%/2.5%	21922-052	DOCUSATE SODIUM
Encube Ethicals Inc	adapalene and benzoyl peroxide gel, 0.1%/2.5%	21922-052	EDETATE DISODIUM
Encube Ethicals Inc	adapalene and benzoyl peroxide gel, 0.1%/2.5%	21922-052	GLYCERIN

What are the Most Frequently-Used Excipients in ADAPALENE AND BENZOYL PEROXIDE GEL, 0.1%/2.5%?

# Of NDCs	Excipient
3	CARBOMER HOMOPOLYMER TYPE C
3	DOCUSATE SODIUM
3	EDETATE DISODIUM
3	GLYCERIN

Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%: Excipient Strategy, Patent Position and Commercial Opportunities

Last updated: September 24, 2026

Adapalene and benzoyl peroxide gel 0.1%/2.5% is a fixed-dose topical acne product originally commercialized as Epiduo. Its commercial opportunity is primarily in differentiated generics, improved tolerability, packaging, preservative systems, and manufacturing efficiency rather than in broad active-ingredient exclusivity. The formulation challenge is to stabilize an oxidizing peroxide with a retinoid while maintaining uniform dosing, acceptable skin feel, low irritation, and regulatory comparability.

The reference product contains adapalene 0.1% and benzoyl peroxide 2.5% in an aqueous gel. Listed inactive ingredients include carbomer 934P, docusate sodium, edetate disodium, glycerin, isohexadecane, methylparaben, poloxamer 124, poloxamer 182, purified water, and sodium hydroxide (U.S. Food and Drug Administration [FDA], 2008; DailyMed, n.d.).

What is the FDA status of adapalene and benzoyl peroxide gel 0.1%/2.5%?

Epiduo received FDA approval in 2008 under NDA 022320 for the topical treatment of acne vulgaris in patients aged 12 years and older. The product combines a retinoid, adapalene, with the antimicrobial and keratolytic agent benzoyl peroxide (FDA, 2008).

The product is a prescription drug in the United States. Adapalene is also available over the counter as a single agent at 0.1%, including Differin Gel, but the fixed combination with benzoyl peroxide remains a separate prescription product category.

Regulatory attribute	Reference product
Active ingredients	Adapalene 0.1%; benzoyl peroxide 2.5%
Dosage form	Topical gel
U.S. reference product	Epiduo
Original U.S. application	NDA 022320
Initial approval	2008
Indication	Acne vulgaris
U.S. prescription status	Prescription
Main abbreviated pathway	ANDA, subject to FDA requirements for topical semisolid products
Main development issue	Demonstrating pharmaceutical and therapeutic equivalence for a complex topical gel

A generic applicant must address active ingredients, strength, dosage form, route of administration, formulation performance, drug release, physical characteristics, and, where required, comparative clinical or pharmacodynamic evidence. FDA’s product-specific guidance for adapalene and benzoyl peroxide topical products is the principal regulatory reference for development planning (FDA, n.d.-a).

What excipients are used in the reference adapalene and benzoyl peroxide gel?

The reference excipient system performs several distinct functions:

Excipient	Primary formulation role	Strategic relevance
Carbomer 934P	Gelling and viscosity control	Controls spreadability, residence time, and dose uniformity
Poloxamer 124	Surfactant and solubilization aid	Supports dispersion and wetting
Poloxamer 182	Surfactant and emulsion stabilization	Helps manage hydrophobic ingredients
Docusate sodium	Wetting and surfactant function	Improves dispersion of benzoyl peroxide
Glycerin	Humectant	Supports skin feel and reduces drying perception
Isohexadecane	Emollient and sensory modifier	Reduces drag and improves slip
Edetate disodium	Chelating agent	Limits trace-metal catalyzed degradation
Methylparaben	Preservative	Controls microbial growth in the aqueous system
Sodium hydroxide	pH adjustment and carbomer neutralization	Establishes gel structure and product pH
Purified water	Vehicle	Continuous phase

The excipient system is commercially important because benzoyl peroxide is poorly water soluble, chemically reactive, and sensitive to catalytic degradation. Adapalene is highly lipophilic and requires effective dispersion or solubilization support. The formulation must prevent agglomeration, preserve active uniformity, and maintain acceptable rheology during storage and use.

How should an excipient strategy manage benzoyl peroxide stability?

Benzoyl peroxide stability is the central formulation risk. The peroxide can decompose in the presence of heat, light, metals, incompatible excipients, and unsuitable processing conditions. Decomposition can reduce potency and generate changes in odor, color, viscosity, or skin tolerability.

A practical excipient strategy should include:

1. Low-metal raw materials and controlled equipment contact surfaces.
2. Chelation using an agent such as edetate disodium where compatibility and regulatory status support its use.
3. Controlled pH rather than aggressive alkalinity.
4. Protection from oxygen, light, and heat during filling and storage.
5. Avoidance of reducing agents and peroxide-reactive impurities.
6. Tight control of benzoyl peroxide particle size and dispersion.
7. Packaging that limits repeated exposure to air and contamination.

The formulation should not rely on excipient selection alone. Manufacturing controls, bulk hold time, filling conditions, container closure integrity, and shipping temperature are material contributors to product quality.

What excipient changes create the lowest regulatory risk?

The lowest-risk strategy is generally a Q1/Q2-oriented formulation that uses the same inactive ingredients as the reference product at the same or closely justified levels. This approach reduces the risk of differences in viscosity, release, skin deposition, preservative performance, and irritation.

A more substantial excipient change may create a commercial advantage but can increase regulatory burden. Examples include:

• Replacing methylparaben with an alternative preservative.
• Removing parabens through a preservative-free package.
• Replacing isohexadecane with another emollient.
• Using a different carbomer grade.
• Changing surfactant ratios to improve active dispersion.
• Adopting a polymeric delivery system or microencapsulation.

These changes require comparative characterization and stability data. For a U.S. ANDA, an excipient change that materially alters release, skin penetration, or local tolerability can make the product more difficult to establish as equivalent.

What formulations are protected by the original Epiduo patent estate?

The original product was protected by patents directed to combinations of adapalene and benzoyl peroxide, pharmaceutical compositions, and related formulation concepts. The exact Orange Book listing and expiration status must be checked against the current FDA Orange Book because patent listings can change through delisting, expiration, pediatric extensions, or administrative updates (FDA, n.d.-b).

The core commercial distinction is now between:

• Expired or expiring composition-of-matter and formulation rights covering the original fixed combination.
• Any remaining method-of-use or formulation claims.
• Later patents directed to higher-strength adapalene products, delivery systems, packaging, manufacturing processes, or specific excipient systems.
• Patent rights outside the United States, where prosecution and term dates differ.

A generic manufacturer should conduct a claim-by-claim review rather than assume that the end of a listed patent removes every risk. The relevant questions include whether a claim covers the exact 0.1%/2.5% strength, whether it requires a particular excipient or particle size, and whether the claim is directed to use, composition, or manufacture.

When does adapalene and benzoyl peroxide gel lose exclusivity?

The original fixed combination has long passed its initial new-drug exclusivity period. The remaining market-access issues are primarily patent-related, regulatory, and commercial.

Exclusivity category	Relevance to 0.1%/2.5% gel
New chemical entity exclusivity	Not applicable to the mature combination market
Initial NDA exclusivity	Expired
Pediatric exclusivity	Potentially extended listed patent terms where applicable
Orange Book patents	Must be reviewed for current status and expiration
Generic entry	Available through approved ANDA products
OTC adapalene exclusivity	Applies to single-agent adapalene products, not the fixed combination
Formulation patents	May affect specific differentiated products
Method-of-use patents	Can affect labeling or launch strategy if still enforceable

Paragraph IV risk depends on the live patent set at the time of ANDA filing. A first filer may obtain 180-day generic exclusivity if statutory requirements are met, but this requires a current patent and filing analysis. For a mature topical product, the commercial value of first-filer status must be weighed against litigation cost, launch timing, and the likelihood of multiple ANDA applicants.

How strong is the patent estate for the fixed combination?

The estate is strongest where claims require a narrow formulation architecture, a specific delivery mechanism, a defined particle-size distribution, or a manufacturing process that competitors cannot easily design around. Broad claims covering adapalene and benzoyl peroxide together are more vulnerable after years of prosecution, litigation, and generic development.

Patent strength should be scored across five dimensions:

Dimension	Key diligence question
Claim scope	Does the claim cover the exact concentration and dosage form?
Validity	Are anticipation, obviousness, enablement, or written-description challenges credible?
Design-around risk	Can a generic change an excipient or process without losing equivalence?
Geographic reach	Does protection extend beyond the United States?
Enforcement value	Can infringement be detected from the marketed product or only from confidential manufacturing steps?

Manufacturing-process claims may be difficult to enforce because the relevant steps occur inside a competitor’s facility. Product-by-process and formulation claims are usually more commercially useful when their limitations can be identified through product testing or regulatory filings.

What commercial opportunities exist for excipient-driven differentiation?

The most attractive opportunities are products that improve use without materially increasing regulatory complexity.

Lower-irritation gels

Adapalene and benzoyl peroxide can cause dryness, erythema, peeling, burning, and stinging. A formulation that reduces initial irritation may improve adherence. Potential approaches include:

• More controlled benzoyl peroxide release.
• Better humectant and emollient balance.
• Lower-friction gel rheology.
• Reduced surfactant irritation.
• Skin-compatible polymer systems.
• Controlled pH and buffering.

The commercial claim should focus on measured tolerability, not simply the presence of a different excipient.

Preservative-free packaging

A preservative-free product could appeal to patients with sensitivity concerns. The opportunity depends on a container that prevents microbial ingress during repeated use. Airless pumps, unit-dose systems, and sealed metered dispensers are potential platforms.

The cost tradeoff is material. Airless packaging can increase component cost, filling complexity, and device qualification requirements. It can also create a stronger product presentation in dermatology channels.

Metered-dose delivery

A metered pump can improve dose consistency and reduce contamination compared with an open tube. The device may support premium positioning, adherence programs, and reduced product waste. The product must demonstrate that the device does not alter active stability, delivered dose, priming behavior, or residual content.

Improved sensory profile

Isohexadecane and polymer selection materially influence spreadability, tack, whitening, and residue. A clear, fast-spreading, low-tack gel may compete more effectively with separate adapalene and benzoyl peroxide products, especially among patients who discontinue treatment because of cosmetic disadvantages.

Climate-stable formulations

A formulation designed for high-temperature and high-humidity markets can support geographic expansion. Relevant development targets include:

• Reduced viscosity drift.
• Lower benzoyl peroxide decomposition.
• Improved container compatibility.
• Resistance to phase separation.
• Stable active content after transport stress.

This opportunity is particularly relevant in markets with weak cold-chain infrastructure, although the product should generally be designed for ambient distribution rather than refrigerated handling.

How does the fixed combination compare with competing acne products?

Product category	Main advantage	Main limitation	Excipient opportunity
Adapalene 0.1% alone	Lower active complexity and OTC availability	No benzoyl peroxide antimicrobial component	Better moisturization and sensory profile
Benzoyl peroxide alone	Antimicrobial and keratolytic activity	Irritation and bleaching concerns	Controlled release, low-irritancy vehicle
Adapalene/BPO 0.1%/2.5%	Single-product combination therapy	Higher irritation burden and prescription access	Tolerability, metered delivery, packaging
Adapalene/BPO 0.3%/2.5%	Higher adapalene strength	Greater irritation and narrower tolerability	Controlled delivery and barrier-supportive excipients
Clindamycin/BPO products	Antibiotic combination	Antimicrobial resistance and antibiotic stewardship concerns	Non-antibiotic fixed combinations
Separate retinoid plus BPO	Flexible titration	More products and lower adherence	Co-pack or coordinated delivery

The 0.1%/2.5% product occupies a broad treatment position because it combines a topical retinoid with benzoyl peroxide while using a lower adapalene concentration than the 0.3% product. Its main differentiation challenge is tolerability and convenience.

What generic launch risks exist?

Generic entry risks are more complex than the active ingredient concentrations suggest. Key risks include:

• Failure to match rheology and spreadability.
• Benzoyl peroxide degradation during accelerated stability testing.
• Inadequate preservative effectiveness.
• Active stratification or nonuniformity during storage.
• Different release or permeation behavior.
• Tube or pump adsorption.
• Incompatibility between the formulation and packaging.
• Visible color or odor changes.
• Batch-to-batch variation in peroxide particle size.
• Product complaints related to burning, peeling, or drying.

A low-cost tube product may be adequate for a basic generic strategy. A premium generic strategy should prioritize airless packaging, better skin feel, and validated tolerability. The latter approach can support dermatology distribution and private-label partnerships but may require greater investment in device development and clinical usability.

Which companies are positioned to compete?

Competition includes the original branded manufacturer, established topical generic companies, contract development and manufacturing organizations, and consumer-health companies with dermatology portfolios. The strongest competitors are likely to have:

• Existing semisolid manufacturing capacity.
• Access to benzoyl peroxide handling expertise.
• Approved topical ANDA infrastructure.
• Dermatology sales relationships.
• Packaging engineering capability.
• A portfolio that includes adapalene, benzoyl peroxide, or other acne products.

Commercial success will depend less on simple ingredient access than on reliable supply, stable peroxide performance, channel access, and the ability to obtain favorable formulary or pharmacy substitution economics.

What licensing and partnering opportunities exist?

The most practical licensing opportunities are formulation and platform transactions rather than licenses to the basic active ingredients. Potential deal structures include:

1. Out-licensing of a differentiated gel platform to a generic or specialty pharmaceutical company.
2. Contract development agreements for Q1/Q2-matched formulations.
3. Device partnerships for airless or metered-dose delivery.
4. Regional licensing in markets where local registration and distribution are fragmented.
5. Private-label dermatology supply for pharmacies, teledermatology providers, and specialty distributors.
6. Technology licensing for stabilized benzoyl peroxide dispersion or controlled release.

A licensor should protect formulation know-how through patents where possible and trade secrets for process parameters, raw-material specifications, mixing order, deaeration, and filling controls.

What is the revenue exposure and market opportunity?

The product has a mature, price-sensitive revenue profile. Revenue exposure is concentrated in prescription acne treatment, pharmacy substitution, dermatology prescribing, and access through insurance or cash-pay channels. The opportunity is greater for products that reduce treatment discontinuation or improve convenience than for an undifferentiated tube generic.

The most defensible commercial positions are:

• A low-cost, reliable ANDA product.
• A lower-irritation formulation with supporting clinical data.
• A preservative-free or airless-pump product.
• A formulation optimized for hot and humid markets.
• A co-pack or adherence program combining the fixed gel with moisturizers and sunscreen.
• A private-label or teledermatology product with efficient fulfillment.

Premium pricing requires evidence of improved patient experience, reduced waste, dosing consistency, or channel value. Excipient changes alone do not establish a premium position.

Key Takeaways

• Adapalene and benzoyl peroxide gel 0.1%/2.5% is a mature fixed-dose acne product with established FDA approval and generic competition.
• The central technical problem is maintaining benzoyl peroxide stability while dispersing adapalene uniformly in a cosmetically acceptable gel.
• Carbomer, poloxamers, docusate sodium, glycerin, isohexadecane, edetate disodium, methylparaben, sodium hydroxide, and water form the core reference excipient system.
• The lowest regulatory-risk path is a reference-matched formulation with tight control of particle size, viscosity, pH, microbial quality, and packaging.
• The strongest commercial opportunities are lower-irritation delivery, preservative-free packaging, metered dosing, improved sensory properties, and climate-stable products.
• Orange Book patents and any pediatric extensions must be reviewed at the time of filing or launch. Patent risk is claim-specific and cannot be assessed from the active ingredients alone.
• A differentiated excipient strategy is most valuable when linked to measurable tolerability, stability, dosing, or adherence benefits.

FAQs

Is adapalene and benzoyl peroxide gel 0.1%/2.5% available as a generic?

Yes. Generic versions of the fixed-dose topical combination have been approved through the ANDA pathway. Product availability varies by market and supplier.

Can a generic replace methylparaben in the formulation?

Potentially, but the change may affect preservative effectiveness, irritation, stability, and formulation equivalence. The applicant must justify the alternative preservative through regulatory and product-performance data.

Is benzoyl peroxide compatible with all carbomer grades?

No. Carbomer grade, neutralization level, impurity profile, and processing conditions can affect peroxide stability, viscosity, and active uniformity. Compatibility must be established through formulation and stability studies.

Does airless packaging create patent protection?

Airless packaging may support device or packaging patent claims, but it does not automatically create exclusivity. Patentability depends on the specific device structure, dosing mechanism, closure system, and claim scope.

Can a lower-irritation version obtain premium pricing?

Yes, if the product demonstrates a meaningful benefit through tolerability, adherence, usability, or reduced discontinuation. A different excipient list without supporting performance evidence is unlikely to sustain a strong premium.

References

1. DailyMed. (n.d.). Epiduo: Adapalene and benzoyl peroxide gel prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (2008). Epiduo adapalene and benzoyl peroxide gel, NDA 022320 approval information. https://www.accessdata.fda.gov/

3. U.S. Food and Drug Administration. (n.d.-a). Product-specific guidances for generic drug development: Adapalene and benzoyl peroxide topical products. https://www.accessdata.fda.gov/

4. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm